Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Medtronic
Argus Health
Boehringer Ingelheim
Harvard Business School
Merck
Moodys
Covington

Generated: January 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,712,279

« Back to Dashboard

Which drugs does patent 5,712,279 protect, and when does it expire?

Patent 5,712,279 protects JUXTAPID and is included in one NDA.

This patent has sixty-five patent family members in thirty countries.

Summary for Patent: 5,712,279
Title: Inhibitors of microsomal triglyceride transfer protein and method
Abstract:Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein Z, X.sup.1, X.sup.2, x and R.sup.5 are as defined herein.
Inventor(s): Biller; Scott A. (Hopewell, NJ), Dickson; John K. (Eastampton, NJ), Lawrence; R. Michael (Yardley, PA), Magnin; David R. (Hamilton, NJ), Poss; Michael A. (Lawrenceville, NJ), Robl; Jeffrey A. (Newtown, PA), Sulsky; Richard B. (Franklin Park, NJ), Tino; Joseph A. (Lawrenceville, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:08/548,811
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,712,279

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-001 Dec 21, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Sign Up
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-002 Dec 21, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Sign Up
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-003 Dec 21, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Sign Up
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-004 Apr 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Sign Up
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-005 Apr 23, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Sign Up
Aegerion JUXTAPID lomitapide mesylate CAPSULE;ORAL 203858-006 Apr 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 5,712,279

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 001795 ➤ Sign Up
Austria 219514 ➤ Sign Up
Austria 283851 ➤ Sign Up
Australia 3406493 ➤ Sign Up
Australia 4763196 ➤ Sign Up
Australia 670930 ➤ Sign Up
Australia 690125 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Moodys
Daiichi Sankyo
Mallinckrodt
Dow
Boehringer Ingelheim
US Army
QuintilesIMS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.